StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the stock.
A number of other equities research analysts have also recently issued reports on DBVT. HC Wainwright upped their price target on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a report on Tuesday, September 24th.
View Our Latest Stock Analysis on DBV Technologies
DBV Technologies Trading Down 2.2 %
DBV Technologies’s stock is going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, November 28th.
Institutional Investors Weigh In On DBV Technologies
A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. lifted its stake in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) by 6.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after buying an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. 71.74% of the stock is owned by institutional investors and hedge funds.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
Read More
- Five stocks we like better than DBV Technologies
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Rocket Lab is the Right Stock for the Right Time
- Most active stocks: Dollar volume vs share volume
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- What is the Shanghai Stock Exchange Composite Index?
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.